David Wofsy
Professor Emeritus · University of California (San Francisco) School of Medicine
Credentials: · ·
History
Internal Medicine
University of California
Research
Arthritis & Rheumatology · 2019 · 1,900 citations
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
Journal of the American Society of Nephrology · 2009 · 800 citations
The immune cell landscape in kidneys of patients with lupus nephritis
Nature Immunology · 2019 · 681 citations
35 papers
22 papers
21 papers
20 papers
- AD
18 papers
18 papers
18 papers
17 papers · 4 as a fellow
Grants
- 2014–2022
PEARL: Pathway Exploration and Analysis in Renal Lupus
National Institute of Arthritis and Musculoskeletal and Skin Diseases · UH2
PI · $9M · Feinstein Institute for Medical Research
- 2014–2020
Autoimmunity Center of Excellence Clinical Research Program
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $31.4M · University of California, San Francisco
- 2003–2015
Autoimmunity Center of Excellence
National Institute of Allergy and Infectious Diseases · U19
Contact PI · $6.3M · University of California, San Francisco
- 1978–2009
Academic Rheumatology and Clinical Immunology
National Institute of Arthritis and Musculoskeletal and Skin Diseases · T32
Contact PI · $3.4M · University of California, San Francisco
Clinical trials
- 2008–2014
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Principal investigator · Completed · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
- 2022–2028
VIBRANT: VIB4920 for Active Lupus Nephritis
Study chair · Recruiting · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
- 2017–2023
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
Study chair · Terminated · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)
- 2015–2018
Autologous Polyclonal Tregs for Lupus
Study chair · Terminated · Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)